浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

目的探讨术后腹腔化疗联合静脉化疗与单纯静脉化疗对浆膜受侵的结直肠癌患者的I临床疗效。方法前瞻性非随机将332例浆膜受侵的结直肠癌根治术后患者分为联合化疗组（行腹腔化疗联合静脉化疗166例）和静脉化疗组（行单纯静脉化疗166例）,比较两组患者术后腹腔局部复发率、腹腔转移率、肝及其他远处转移率和患者3年、5年总体生存率。结果联合化疗组和静脉化疗组3年、5年总体生存率：ⅡB期两组病例比较,差异无统计学意义（X^2=0.612,P=0.434）;Ⅲ期病例两组比较,差异有统计学意义（X^2=3.989,P=0.046）。联合化疗组的腹腔局部复发率（1.9％）、腹腔转移率（3.8％）和肝转移率（3.8％）均显著低于静脉化疗组的8.2％、9.5％和10.1％（P〈0.05）,而两组其他远处（肺、骨、脑）转移率（5.1％比3.8％）比较,差异无统计学意义（P〉0.05）。联合化疗组中,使用奥沙利铂组腹腔转移率和肝转移率（0.9％和0.9％）均显著低于使用顺铂组（8.8％和8.8％,P〈0.05）,两组局部复发率和远处转移率（0.9％和4.7％比3.5％和5.3％）比较,差异无统计学意义（P〉0.05）。结论联合化疗可显著降低浆膜受侵的结直肠癌根治术后患者局部复发率、腹腔转移率与肝转移率,腹腔化疗中奥沙利铂在预防腹腔广泛转移和肝转移方面较顺铂效果更佳。     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

腹腔镜下结直肠癌肝转移同时根治切除的临床研究

目的研究腹腔镜结直肠癌根治性切除联合腹腔镜切除治疗结直肠癌肝转移的临床疗效。 方法回顾性分析2014年1月至2015年12月确诊为同时性结直肠癌肝转移患者90例资料。分为腹腔镜组(n＝45)和开腹组(n＝45),采用SPSS21.0统计软进行数据分析,术中术后指标采用( ±s)表示,独立t检验;术后并发症采用χ²检验;偏态分布的资料采用M(Qn)和M(范围)表示,应用Mann－Whitney U检验。P<0.05为差异有统计学意义。 结果两组患者手术时间、术中出血量、术中输血量、神经浸润及脉管侵犯等差异无统计学意义(P>0.05)。术后情况：两组患者在进食时间、术后TBIL、术后ALT、并发症及住院时间差异无统计学意义(P>0.05);而腹腔镜组入住ICU的患者时间为(2.1±1.6) d,明显短于开腹组(1.0±06) d (t＝1.804, P<0.05)。随访结果：两组术后1、2年累积无瘤生存率和生存时间差异无统计学意义(P>0.05)。 结论腹腔镜结直肠癌根治性切除术联合腹腔镜肝切除术在安全性优于腹腔镜结直肠癌根治性切除治疗联合开腹肝切除术,但两种治疗方法在术后并发症发生率及临床预后等方面效果相当。     

腹腔镜结直肠癌根治术的临床体会

目的:探讨腹腔镜结直肠癌根治术的临床效果。方法:回顾分析2011年3月至10月为26例结直肠癌患者行腹腔镜结直肠癌根治术的临床资料,并总结手术方式及随访结果。结果:手术时间105～315 min,平均185 min;术中出血量100～320 ml,平均175 ml;术后胃肠功能恢复时间1～4 d,平均1.8 d;标本切缘均阴性,清扫淋巴结总数10～22枚,平均15枚。术后未发生腹腔出血、吻合口漏及狭窄等并发症;术后住院7～10 d,平均8 d。随访3～10个月,平均8个月,均无转移、复发及切口种植。结论:腹腔镜结直肠癌根治术安全可行,具有微创、安全、术后康复快、肿瘤根治彻底等优点,在肿瘤根治性、手术时间、近期疗效等方面与传统开腹手术相当,值得推广应用。     

腹腔镜在结肠直肠肿瘤手术中的应用

目的探讨腹腔镜在结肠直肠肿瘤治疗中的应用。方法回顾性分析我院2003年8月-2007年8月行腹腔镜下结肠直肠肿瘤治疗52例的临床资料。结果本组无手术死亡病例。腹腔镜手术时间为150-250min,平均190min。淋巴结切除数10-36个。术后72h病人均恢复胃肠功能。结论腹腔镜下结肠直肠肿瘤手术安全可行,但要掌握好腹腔镜的操作技巧及手术指征。     

结直肠癌辅助门静脉持续灌注化疗与肠腔化疗疗效的对比研究

目的　比较结直肠癌根治术后经门静脉持续灌注 5 FU 7d与术中肠腔一次给药化疗对减少术后肝转移、提高术后远期疗效的作用。方法　行根治性手术的结直肠癌患者 16 2例 ,随机分为门静脉化疗组 (A组 ) 82例和肠腔化疗组 (B组 ) 80例 ,两组的年龄、性别、肿瘤部位、肿瘤大小、Dukes′分期等差异均无显著意义 (P >0 0 5 )。A组术中经大网膜静脉向门静脉插管 ,导管远端引出腹壁固定 ,术后即从门静脉导管持续给予 5 FU 1g/d ,连续 7d ,B组术中用肠腔化疗加一次性经大网膜静脉注射 5 FU。用SPSS8 0分析比较两组的近期并发症及远期疗效。结果　A组术后并发症较多 ,但平均住院时间及生存曲线等指标两组差异无显著意义 (P >0 0 5 )。全组 5年生存率 76 7% (A组74 3% ,B组 79 2 % )。用Gehan法检验两组生存曲线 ,其差异也无显著意义。全组肝转移率为19 8%。多因素分析显示 ,影响本组预后的因素为Dukes′分期 (P <0 0 5 )。结论　结直肠癌根治术后经门静脉持续灌注 5 FU 7d的辅助化疗方法与肠腔化疗对预防肝转移、提高生存率有一定的作用 ,二者疗效相当 ,但后者更简便     

腹腔镜与开腹结直肠癌根治术后并发症的分析

结直肠癌是消化道常见恶性肿瘤.手术是其主要的治疗方式,开腹手术和腹腔镜手术是两种主要的术式.术后吻合口瘘、吻合口出血、肠梗阻、排尿功能与性功能障碍是其常见并发症,乳糜漏、切口感染、肺部感染、切口肿瘤种植等也时有发生.两种手术方式比较,腹腔镜手术并不增加术后并发症发生率,某些并发症甚至低于开腹手术.腹腔镜能安全应用于结直肠癌根治术中.     

腹腔镜结直肠癌根治术疗效分析

目的 探讨腹腔镜结直肠癌根治术的疗效.方法 比较2000年9月至2004年12月福建医科大学附属协和医院收治的99例腹腔镜结直肠癌根治术(腹腔镜组)患者和198例开腹结直肠癌根治术(开腹组)患者局部复发及生存情况的差异.两组各随访时间段的局部复发率、生存率计算采用寿命表法,局部复发率及生存率的比较采用Wilcoxon(Gehan)检验或X2检验及Fisher确切概率法,复发间隔时间、生存时间的比较均采用非参数Wilcoxan秩和检验.结果 腹腔镜组2、3年局部复发率均为3.0%,总的局部复发率3.0%(3/99);开腹组2、3年局部复发率分别为2.6%和4.0%,总的局部复发率为3.5%(7/198),两组局部复发率比较差异无统计学意义(χ2=0.002,P>0.05).两组局部复发的患者中位生存时间分别为15个月(7～24个月)和11个月(2～28个月),差异无统计学意义(U-15.500,P>0.05).两组局部复发的患者1年生存率分别为33.3%和42.9%,2年生存率分别为0和42.9%,差异无统计学意义(χ2=0.120,P>0.05).结论 腹腔镜结直肠癌根治术与开腹结直肠癌根治术有同样的疗效,且安全可行,不会增加肿瘤的复发率.     

开腹与腹腔镜结直肠癌根治术后并发症的分级与评估

目的:探讨开腹手术与腹腔镜结直肠癌根治术后并发症的分级及评估。方法:2009年6月至2011年8月前瞻性地连续纳入158例腹腔镜结直肠癌根治术患者(腹腔镜组)及158例开腹结直肠癌根治术患者(开腹组),对比两组患者术后4周内并发症发生情况。分三步评价并发症的严重性。首先,将术后所有并发症根据Clavien分级进行分类。第二步,5位研究员分别独自应用直观叙述问卷模式对并发症的严重程度进行分级,0表示无术后并发症,100表示术后死亡。第三步,分别用中位数、最低及最高值对两组患者术后并发症进行评价。结果:开腹组术后并发症发生率显著高于腹腔镜组(23.4%vs.13.9%,P<0.05),术后并发症严重程度高于腹腔镜组。在敏感性比较中,中位数、最高值及最低值取得了类似结果。结论:开腹结直肠癌根治术术后并发症发生率显著高于腹腔镜手术,术后并发症严重程度亦高于腹腔镜手术。应用此分级评估法可对开腹与腹腔镜结直肠癌根治术术后并发症的发生做出直接评价。     

腹腔镜下结直肠癌及肝转移癌一期同时切除术的临床应用

目的：探讨腹腔镜下一期同时切除结直肠癌和肝转移癌的安全性及可行性。方法回顾性分析2011年1月至2013年10月期间在中山大学孙逸仙纪念医院完成的腹腔镜下结直肠癌和肝转移癌一期同时切除手术的11例患者的病例资料,对该术式的可行性（中转开腹率、手术时间及术中出血量）、安全性（术后并发症）及疗效（术后恢复、复发及生存情况）进行评估。结果全组11例患者手术均取得成功,无中转开腹病例。手术时间（284．6±28．8） min,术中出血量（322．7±75．4） ml,术后肛门排气时间（2．9±0．7） d,术后住院时间（12．3±1．9） d。全组患者术后未出现肠瘘、胆瘘、腹腔大出血、腹腔感染及肝功能衰竭等并发症。术后随访时间3～35月,除1例患者因肿瘤转移死亡外,其余病例未见肿瘤复发。结论对于经过选择的合适病例,腹腔镜下同时切除结直肠癌和肝转移癌是安全、可行的。     

腹腔镜和开腹结直肠癌根治术的远期疗效研究

目的 探讨腹腔镜和开腹结直肠癌根治术在远期疗效方面的差异。方法将1996年1月至2000年9月问215例需行结直肠癌根治术的患者根据本人意愿非随机地分为开腹组和腹腔镜组，对比两组患者术后的5年生存率、局部复发率和远处转移及远期并发症。结果开腹组128例，腹腔镜手术组87例；两组在年龄、性别、肿瘤分期方面差异均无统计学意义（P〉0．05）。5年累计生存率开腹组70％，腹腔镜组78％，两组比较差异无统计学意义（P〉0．05）。开腹组局部复发33例，远处转移34例，切口种植2例，切口疝4例，粘连性肠梗阻30例；腹腔镜组局部复发20例，远处转移22例，切口种植1例，切口疝2例，粘连性肠梗阻11例。两组局部复发率、远处转移率、切口种植率和切口疝发生率比较差异均无统计学意义（P值分别为0．641、0．505、1．00和1．00）；但腹腔镜组术后粘连性肠梗阻发生率较开腹组少（P〈0．05）。结论腹腔镜结直肠癌根治术远期疗效与开腹手术相似，但术后远期并发症少，值得推广。